Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912312 · ClinicalTrials.gov registry record · Phase 2
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
A Phase 2 study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 805
- Enrollment target
- 12
- Study locations
NCT02912312 is a Phase 2 study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 805 participants, above the 467-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (72% higher). The trial reports 12 study locations across 8 states.
The verdict
NCT02912312, a Phase 2 study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 805 participants
- Enrollment target
- 12
- Study locations
Study Summary
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- RADIATION Radiation Therapy
- RADIATION Hypofractionated Radiation Therapy
Study Locations (12)
Indiana
- Community MD Anderson Cancer Center East - Indianapolis
- Community MD Anderson Cancer Center South - Indianapolis
- Community MD Anderson Cancer Center North - Indianapolis
Florida
- Baptist - MD Anderson Cancer Center - Jacksonville
- Orlando Health Cancer Institute - Orlando
Texas
- M D Anderson Cancer Center - Houston
- UT Health San Antonio - MD Anderson Cancer Center - San Antonio
Arizona
- MD Anderson Cancer Center (Banner) - Gilbert
California
- Scripps- MD Anderson Cancer - San Diego
Colorado
- MD Anderson Cancer Center (Banner)- Northern Colorado - Greeley
New Jersey
- Cooper Hospital University Medical Center - Camden
Ohio
- Ohio Health - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 805 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02912312
The ClinicalTrials.gov registry entry for NCT02912312 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 805 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 467-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (72% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02912312 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Indiana, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT02912312 about?
NCT02912312 is a clinical study titled "Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer". To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling ...
What is the current status of trial NCT02912312?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 805 participants. The study started on 2017-02-23. Estimated completion is 2031-02-28.
What conditions does trial NCT02912312 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIIC Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7.
What interventions are being tested in trial NCT02912312?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Radiation Therapy (RADIATION), Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02912312?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02912312 being conducted?
This trial has 12 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Metformin and Nightly Fasting in Women With Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Invasive Breast Carcinoma
All registered trials for this condition
Stage II Breast Cancer AJCC v6 and v7
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.